ImmunityBio, Inc. (IBRX) Q3 2026 earnings results
ImmunityBio, Inc. (IBRX) reported Q3 2026 results on Nov 9, 2026, 7:39:35 AM ET: GAAP EPS -$0.18 vs. -$0.05 expected (miss by 260.0%); revenue $48.84M vs. $59.23M expected (miss by 17.5%).
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | -$0.18 | -$0.05 | Miss by 260.0% |
| Revenue | $48.84M | $59.23M | Miss by 17.5% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 9, 2026, 7:39:35 AM ET. Nexqual published them 27 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 52.3% from $32.06M; GAAP diluted EPS was -$0.18 vs. -$0.07 (−157.1%).
Stock reaction
The results came out before the market opened. IBRX closed at $7.11 on November 9, 2026, down 17.7% from its $8.64 close on November 6, 2026 before the results. Latest: $6.99 as of 11:32 AM ET, −19.1% since the pre-release close.
Questions and answers
Did ImmunityBio, Inc. beat earnings expectations?
No. ImmunityBio, Inc. reported GAAP EPS of -$0.18 against an average analyst estimate of -$0.05 (miss by 260.0%), and revenue of $48.84M against $59.23M expected (miss by 17.5%).
What were ImmunityBio, Inc.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of -$0.18 and revenue of $48.84M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 52.3% from $32.06M; GAAP diluted EPS was -$0.18 vs. -$0.07 (−157.1%).
When did ImmunityBio, Inc. report Q3 2026 earnings?
Nov 9, 2026, 7:39:35 AM ET, in an SEC 8-K filing (Item 2.02).
How did IBRX stock react to the earnings?
The results came out before the market opened. IBRX closed at $7.11 on November 9, 2026, down 17.7% from its $8.64 close on November 6, 2026 before the results. Latest: $6.99 as of 11:32 AM ET, −19.1% since the pre-release close.
More on IBRX
IBRX stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 9, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:32 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:32 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt